Our investigation employing HCC cell lines and the AKT/c-MET mouse HCC model suggests that combination of anti-MEK and anti-mTOR inhibitors could be a new therapeutic approach for human HCC treatment. The gene discussed is AKT1; the disease is hepatocellular carcinoma.